Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
03/30/2016 +50% ?? 44 ??
03/29/2016 +50% ?? 29 ??
03/28/2016 +50% ?? 19 ??
Date Open High Low Close Volume Change Change % Adj. Close
03/24/2016 7.24 13.99 7.24 12.60 232.71k 4.31 51.99% 12.60
03/23/2016 4.56 9.00 4.49 8.29 152.72k 3.80 84.63% 8.29
03/22/2016 3.50 4.50 2.80 4.49 84.42k 1.24 38.15% 4.49
03/21/2016 2.35 3.25 2.30 3.25 52.76k 0.90 38.30% 3.25
Court-filed documents continue, “In the event that definitive Loan Documents are not signed by the Debtor and the Lender on or before April 7, 2016 or the Bankruptcy Court fails to enter the DIP Order by April 29, 2016, then the Debtor’s obligations with respect to the ‘Breakup Fee’ shall terminate and be of no further force or effect
Mar 22 2016 - Black Horse Capital LP, a North Carolina-based hedge fund, is the stalking horse investor who will make $10M bid
[A stalking horse bid is basically an attempt by a bankrupt company to determine the market price for its assets before an auction takes place. The stalking horse bidder, chosen by the company, makes the first offer.]
MARCH 24, 2016 - As previously reported, “[W]e are pleased to submit the following amended letter and attached amended term sheet for debtor-in-possession financing in the principal amount of $3,000,000 and exit financing in the principal amount of $11,000,000 to KaloBios Pharmaceuticals.” $14M bid
total shares short last week 149.000
total shares trade last week 521.000
30% total volume short
Short Volume
Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20160324|KBIOQ|64406|0|230568|O
20160323|KBIOQ|41481|0|152715|O
20160322|KBIOQ|25595|0|83421|O
20160321|KBIOQ|18234|0|52761|O
20160318|KBIOQ|1055|0|5711|O
Short Volume last week = 149.716 shares
Shs Float 1.030.000
Current Short 03/15/2016 32,424 shares
+/- 182.000 shares short
Date Open High Low Close Volume AdjClose
2016/03/24 7.24 13.99 7.24 12.60 233,208 12.60
2016/03/23 4.5600 9.00 4.49 8.2900 152,715 8.29
2016/03/22 3.50 4.50 2.80 4.49 84,421 4.49
2016/03/21 2.35 3.25 2.30 3.25 52,761 3.25
2016/03/18 2.2600 2.35 2.24 2.35 5,713 2.35
KBIOQ +60%
Insider Holders 3.090.146 shares - 75%
Shs Outstand 4.120.000
Shs Float 1.030.000 - 25%
Short Interest 60,599 Feb 12, 2016 - 6%
KBIOQ 12.00 +3.71 +44.75%
KBIOQ 12.00 +3.71 +44.75%
KBIOQ 12.00 +3.71 +44.75%
KBIOQ 12.00 +3.71 +44.75%
KaloBios Pharmaceuticals LOI Amendment Approved
http://bankruptcompanynews.com/kalobios-bankruptcy-3-24-16/
KBIOQ +35%
KBIOQ +35%
KBIOQ +35%
KBIOQ +20%
KBIOQ +20%
KBIOQ +20%
Insider Holders 3.090.146 shares - 75%
Shs Outstand 4.120.000
Shs Float 1.030.000 - 25%
Short Interest 60,599 Feb 12, 2016 - 6%
Insider Holders*
Individual/Entity Most Recent Trans. Shares Owned as of Trans. Date
ANTHION PARTNERS II LLC
Beneficial Owner (10% or more) Purchase
Dec 16, 2015 756,420
Dec 16, 2015
BIESTEK MAREK
Director Purchase
Dec 16, 2015 250,000
Dec 16, 2015
FERNANDEZ THOMAS EDWARD
Director Purchase
Dec 16, 2015 6,821
Dec 16, 2015
HARRISON MICHAEL WAYNE
Director Purchase
Dec 16, 2015 1,705
Dec 16, 2015
SHKRELI MARTIN
Officer Purchase
Nov 24, 2015 2,075,200
Nov 24, 2015
KBIOQ +84.63%
KBIOQ KaloBios Pharmaceuticals, Inc.
8.29 +3.80 (+84.63%)
Centers for Disease Control and Prevention
U.S. Consumer Product Safety Commission Report
"We estimated the risk of cancer from exposure to this flooring and it’s low."
http://www.cdc.gov/nceh/laminateflooring/default.html
tier changes very confused
http://www.otcmarkets.com/market-activity/otc-tier-changes?search=phot&searchType=symbol
Not BB, but pink
non dtc eligible, with other brokers happened the same.
correct. my mistake
SCHEDULE 13D February 2, 2016
As of November 2, 2015, Aella owns of record 1,843,370 Shares (or approximately 12.7% of the total number of Shares of Common Stock of the Issuer currently outstanding)
$ 1.0232 ? 0.0731 (7.69%)
Rennova Health, Inc. Granted U.S. Trademark for StableSpot(R), a Laboratory Specimen Transport System
New System Will Lead to Drastic Reduction in Laboratory Supply Costs
http://finance.yahoo.com/news/rennova-health-inc-granted-u-220000483.html
* NEWS *
Rennova Health, Inc. Granted U.S. Trademark for StableSpot(R), a Laboratory Specimen Transport System
New System Will Lead to Drastic Reduction in Laboratory Supply Costs
WEST PALM BEACH, FL--(Marketwired - Jan 28, 2016) - Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAW), which owns and operates a diverse family of healthcare companies, received a trademark from the United States Patent and Trademark Office for StableSpot®, a clinical dry specimen transport kit for collection, stabilization, and transport of urine, serum, plasma, and blood. This innovative new approach will provide convenient sample collection for a patient, help protect the integrity of samples, cut down on packing and shipping concerns, and reduce total laboratory supply costs.
"One of the greatest challenges to providing a diagnostic service directly to an individual is the collection, transport and maintaining the stability of specimens," remarked Seamus Lagan, CEO of Rennova Health, Inc. "StableSpot® provides a viable solution to an area in our business that has historically been complicated and costly."
As well as the inconvenient traditional collection methods, many laboratory specimens require stabilization, refrigeration, and/or freezing in order to maintain specimen stability during transit. To mitigate against specimen degradation, shipments would contain ice packs, coolers, and other special shipping equipment. Now, StableSpot's technology allows dry specimens to take the place of liquid ones.
StableSpot® Dry-Specimen Collection Kits will be used by Rennova Health, Inc., at their five clinical reference laboratories nationwide. For more information about StableSpot® and Rennova Health, please contact Sebastien Sainsbury at (561) 666-9818 or ssainsbury@rennovahealth.com.
Contract Is Largest for Clinlab Since It Was Acquired by Rennova Health
Georgia's Largest Public Health Agency Signs Deal With Clinlab for New Lab Information System
Contract Is Largest for Clinlab Since It Was Acquired by Rennova Health
http://finance.yahoo.com/news/georgias-largest-public-health-agency-220000597.html
RNVA
RNVA
Rennova Health Inc Bullish Signal Lagan Seamus Is In!
Lagan Seamus New Position in Rennova Health, Inc
Lagan Seamus has filled a SC 13D form regarding Rennova Health, Inc 0.0000 0.00 %. Filing Link: 000101968716004899. Per Lagan Seamus’s filing, the filler now owns 13.1% of the Information Technology-company, holding 1,884,334 shares
Read more: http://www.octafinance.com/rennova-health-inc-bullish-signal-lagan-seamus-is-in/341472/#ixzz3yUMJx3Y0
News
Rennova Health to Present at Source Capital Group's 2016 "Disruptive Growth & Healthcare" Conference on February 11
Presentation Begins at 9 a.m. Eastern Time and Will Be Available via Live Webcast
WEST PALM BEACH, FL--(Marketwired - Jan 27, 2016) - Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAW) announced today that CEO Seamus Lagan will provide a company overview at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 11, 2016 in New York City at 9 a.m. Eastern Time.
Disruptive Growth & Healthcare is an executive conference that features presentations from CEOs, CFOs, COOs, and CMOs of high-growth companies, as well as healthcare companies pioneering new technologies and business models.
The presentation by Seamus Lagan will be available via live webcast at http://wsw.com/webcast/sourcecap1/rnva and an archive will be available through May 11, 2016. Conference information and investor registration may be reached at www.SourceCapitalConference.com.
About Rennova Health, Inc.
Rennova Health, Inc. (NASDAQ: RNVA) provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcome. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. . For more information about Rennova Health, Inc., visit www.rennovahealth.com.
Georgia's Largest Public Health Agency Signs Deal With Clinlab for New Lab Information System
Contract Is Largest for Clinlab Since It Was Acquired by Rennova Health
WEST PALM BEACH, FL--(Marketwired - Jan 26, 2016) - Clinlab, Inc., a subsidiary of Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAW) that develops and markets laboratory information and automation systems, announced today it has entered into an agreement with the Fulton County Department of Health & Wellness to provide technology for faster, more efficient processing and reporting of lab tests.
The Atlanta health department is the largest in Georgia, serving nearly one million people and employing more than 700 healthcare professionals, support staff, and outreach personnel. This is Clinlab's largest deal since it joined the Rennova family of companies, and it is the second-largest transaction in Clinlab's history.
Laboratory information systems, like Clinlab's, are used in hospital-based labs, office-based labs at physician practices, large clinics, as well as in major reference laboratories that handle tens of thousands of tests. For Fulton County, Clinlab will install its system in a variety of work environments, including lab workstations, offices, and mobile devices used in the field. Moreover, the Clinlab system will increase automation and reduce the reliance on manual processing of tests. It will also reduce the Health Department's dependence on outsourced lab services. Consequently, the system has the potential to dramatically reduce the County's spending on laboratory services and expedite test results.
"Fulton County will benefit from faster turnaround of lab tests and significant cost savings," said Allen Wilson, chief operating officer of Clinlab. "In addition, our system will have a positive impact on public health by allowing the providers at the County's clinics to access patient health records that include a more thorough history of laboratory results -- compiled from state electronic health records and third-party labs."
Clinlab has extensive experience working with other public entities, including the University of Florida, the University of New Mexico, Texas A&M University, Florida State Hospital, and Northeast Florida State Hospital. The company recently launched new technology specifically designed for laboratories that handle toxicology testing, such as those labs owned by Clinlab's parent company, Rennova Health. Rennova operates labs across the U.S. that serve the toxicology testing needs of drug and alcohol rehabilitation facilities and pain management clinics.
"Fulton County's selection of Clinlab serves as testament to our product's capacity to meet the unique needs of a major public health department while reducing operating costs and positively affecting the health of the population it serves," said Seamus Lagan, CEO of Rennova Health, Inc. "It's an exciting step for Clinlab and just the beginning of a healthier future for Fulton County."
For more information about Clinlab or Rennova Health, Inc., visit www.rennovahealth.com. Media inquiries may be directed to Meieli Sawyer at msawyer@weinbachgroup.com.
About Rennova Health
Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAW) owns and operates five diagnostics laboratories across the United States that provide clinical testing services specializing in toxicology testing for pain management clinics, drug and alcohol rehabilitation facilities and neurotransmitter testing. It offers its customers a complete, turnkey software product including: a proprietary laboratory ordering and reporting application, an advanced laboratory information management system, electronic health records, and an industry-leading platform for interpreting and reporting complex test results to physicians. Rennova's software is differentiated from that of its competitors by the breadth of its services, each of which is branded separately and is made available to physician groups in whole or in part. The software permits efficient and easy ordering and reporting, electronic health records integration, medical billing services and compliance, and diagnostic interpretation. For more information see www.rennovahealth.com.
About Clinlab, Inc.
Clinlab, Inc. is a turnkey Windows-based, Internet- and web-enabled Laboratory Information management System (LIS) for the modern small to medium sized clinical lab. Designed by medical technologists, Clinlab can be customized to meet the needs of any laboratory acting as a data warehouse for all lab results and includes reporting, data acquisition, label printing, electronic signoff, and more. Clinlab's highly secure remote access features allow it to connect to multi-location databases to view patient orders and results from any location; support electronic communication between labs, physicians, and other departments; and provide managers with a complete set of quality and control tools to meet the custom security needs of their facility, as well as HIPAA and other regulatory requirements. Seamlessly interfacing with other information systems, including HIS/Practice Management/EMR, Clinlab also supports bi-directional interfaces to national and regional reference labs and is dedicated to improving laboratory productivity and compliance.
Rennova Health Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to significant risks and uncertainties, and actual results could differ materially from those projected and Rennova Health cautions investors not to place undue reliance on the forward-looking statements contained in this release. Important factors that could cause Rennova Health's actual results or performance to differ materially from the forward-looking statements include those set forth in Rennova's filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Rennova Health undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances, except as may be required by law.
Contacts
Rennova Health Media Contact:
Sebastien Sainsbury
Email Contact
(561) 666-9818
Investors:
LHA
Kim Golodetz
Email Contact
(212) 838-3777
Investor Presentation
January 11, 2016
http://c.eqcdn.com/_a6d88283dcb83c3a6a99a7e8c3fe4324/rennovahealth/db/122/3505/pdf/LHA+Rennova+Health+Inc++Presentation+-+SF+Jan+2016.pdf
News Up 18%
1.01
+0.16 (+18.56%)